What Has Been Achieved To Date? AGM2026 COMBINATION DOSING BTK inhibitors are a ~US$12bn global market (2025). STRATEGY FOR BTKI FAILURES 140 Oral presentations at ASH 2025 and ASCO 2026,as well as PEER RECOGNITION Total patients treated with azer-cel in selection for a Poster presentation at ASH...
AGM Presentation
Filed with ASX · · 3 pages · English
Release
Earlier from Imugene
- Imugene selected for Poster Presentation at 2026 ASH Meeting
- Positive amendments to Convertible Notes
- Quarterly Activities/Appendix 4C Cash Flow Report
- Further Responses in azer-cel Phase 1b Trial
- Notification of cessation of securities - IMU
Later from Imugene
- Results of 2026 Annual General Meeting
- Director Resignation and Committee Changes
- Imugene Receives $2.1M R&D Tax Refund
